Anderson G, Berk M, Dean O, Moylan S, Maes M (2014) Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 28(1): 1-10.
Anderson G, Kubera M, Duda W, Lason W, Berk M, Maes M (2014) Increased IL-6 trans-signaling in depression: focus on the tryptophan catbolite pathway, melatonin and neuroprogression. Pharmacological Reports 65(6): 1647-54.
Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 75(6): 628-36.
Bortolasci CC, Vargas HO. Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. Journal of Affective Disorders 159: 23-30.
Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe C, Salvado O, Lance Macaulay S, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group (2014) A blood based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Molecular Psychiatry 19(4): 519-526.
Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychotherapy and Psychomatics 83(2): 70-88.
Dean B, Tawadros N, Suk Seo MS, Jeon WJ, Everall I, Scarr E, Gibbons A (2014) Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. International Journal of Neuropsychopharmacology 17:895-906.
Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhaes PV, Otto MW, Frank E, Miklowitz DJ, Berk M, Kinrys G, Nierenberg A (2014) Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. The American Journal of Psychiatry 171(2): 178-86.
Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, the AIBL Research Group, Bush AI (2014) An anemia of Alzheimer’s disease. Molecular Psychiatry doi:10.1038/mp.2013.178
Hare DJ, Lei P, Ayton S, Roberts BR, Grimm R, George JL, Bishop DP, Beavis AD, Donovan SJ, McColl G, Volitakis I, Masters CL, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Doble PA (2014) An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science 5: 2160-2169.
Hung YH, Faux NG, Killilea DW, Yanjamin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI (2014) Altered transition metal homeostasis in Niemann-Pick disease, Type C1. Metallomics 6: 542-53.
Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulau LS, Ellis KA, Szoeke C, Martins RN, Rowe C, Masters C, Ames D, Zhang P (2014) Genetic algorithm with logistic regression for prediction of progression to Alzheimer’s disease. BMC Bioinformatics 15(Suppl 16):S11.
Maes M, Anderson G, Kubera M, Berk M (2014) Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opinion on Therapeutic Targets 18(5): 495-512.
Malhi GS, Berk M (2014) Diagnosing bipolar disorder: Defining thresholds and setting boundaries. Australian and New Zealand Journal of Psychiatry 48(500): 500-504
Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA (2014) Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. Journal of Alzheimer’s Disease 39: 661-8.
Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Ellis KA, Bush AI, Faux NG, Watters DA (2014) Response to comment on Moore et al, Increased risk of cognitive impairment in patients with diabetes is associated with metformin, Diabetes care 36: 2981-2987. Diabetes Care 37: e151. doi: 10.2337/dc14-0278.
Moylan S, Berk M, Dean OM. Samuni Y, Williams LJ, O’Neil A, Hayley AC, Pasco JA, Anderson G, Jacka FN, Maes M (2014) Oxidative & nitrosative stress in depression: Why so much stress? Neuroscience and Biobehavioral Reviews 45C: 46-62.
Opazo CM, Greenough MA, Bush AI (2014) Copper: From neurotransmission to neuroproteostasis. Frontiers in Aging Neuroscience 6: 143.
Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KL, Szoeke C, Macaulay LS, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL (2014) Changes in plasma beta-amyloid in a longitudinal study of aging and Alzheimer’s disease. Alzheimer’s and Dementia 10(1): 53-61.
Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD, AIBL Research Group (2014) Plasma Aβ levels are significantly associated with a transition towards Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. Journal of Alzheimer’s disease 40(1): 95-104.
Sanna L, Stuart AL, Pasco JA, Jacka FN, Berk M, Maes M, O’Neil A, Paolo G, Williams LJ (2014) Atopic disorders and depression: Findings from a large, population-based study. Journal of Affective Disorders 155: 261-265.
Singh AB, Bousman CA, Ng C, Berk M (2014) Antidepressant pharmacogenetics. Current Opinion in Psychiatry 27(1): 43-51.
Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, Doecke J, Bush AI (2014) Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease. Journal of Alzheimer’s Disease 38(4): 809-22.
Vargas HO, Vargas Nunes SO, Barbosa DS, Vargas MM, Certari A, Dodd S, Venugopal K, Maes M, Berk M (2014) Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sciences 102(1): 65-71.
Wong BXW, Hung YH, Bush AI, Duce JA (2014) Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology. Frontiers in Aging Neuroscience 6: 91.
Berk M, Berk L, Dodd S, Fitzgerald PB, de Castella AR, Filia S, Filia K, Brnabic AJM, Kelin K, Montgomery W, Kulkarni J, Stafford L (2013) The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 146: 146-149.
Berk M, Jacka FN, Williams LJ, O’Neil A, Pasco J, Moylan S, Allen N, Stuart A, Hayley A, Byrne M, Maes M (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicines, 11(1): 1-16.
Berk M, Malhi GS, Gray LJ, Dean OM (2013) The promise of N-acetylcysteine in psychiatry. Trends in Pharmacological Sciences 34(3):167-177.
Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush AI, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, Martins RN, and the AIBL Research Group (2013) Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry 18, 875-881.
Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Ian Paul Everall IP (2013) Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Frontiers in Cellular Neuroscience 7: 95.
Dean B, Moller H-J, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ (2013) Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP think-tank. International Journal of Neuropyschopharmacology 17:137-148.
Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P (2013) Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. Journal of Alzheimer’s Disease 34(4): 861-871.
Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D, and the AIBL research group (2013) Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics 26(4): 543-54.
Fernandes BS, Berk M, Turck CW. Steiner J, Goncalves CA (2013) Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Molecular Psychiatry 19: 750-751.
Frey BN, Andreazza AC, Frye MA, Goldstein BI, Malhi GS, Hall GB, Taylor VH, Fernandes BS, Kauer-Sant’Anna M, Dodd S, Lopez-Jaramillo C, Leboyer M, Frangou S Yatham LN, Berk M, Yound T, Kapczinski F (2013) Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Commitee. Australian and New Zealand Journal of Psychiatry, 47: 321-332.
Ghanizadeh A, Berk M (2013) Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Medical Gas Research 3(1): 11.
Gibbons AS, Scarr E, Boer S, Money T, Jeon W-J, Felder C, Dean B (2013) Widespread decreases in cortical muscarinic receptors in a sub-set of people with schizophrenia. International Journal of Neurospsychopharamcology, 16: 37-46.
Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimer’s Research & Therapy, 5: 31.
Hare D, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherney RA, Bush AI, White AR, Masters CL, Roberts BR (2013) Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics 5(12): 1656-1662.
Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Progress in neuro-psychopharmacology and biological psychiatry 47: 7-12.
Lauder S, Chester A, Castle D, Dodd S, Berk L, Klein B, Austin D, Gilbert M, Chamberlain JA, Murray G, White C, Piterman L, Berk M (2013) Development of an online intervention for bipolar disorder www.moodswings.net.au, Psychology, Health & Medicine, 18.
Laws SM, Doeke JD, Martins (2013) Blood-based biomarkers in Alzheimer’s disease: where are we now and where have we to go? – Reply. Neurology, 70: 133-134.
Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P, Australian Imaging Biomarkers and Lifestyle Study of Ageing research group (2013) BDNF Val66Met, AB amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiology of Aging 34: 2457-2464.
Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stöffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush AI Masters CL, Rowe CC, Ames D, Darby D, Maruff P (2013) Three month stability of the CogState brief battery in healthy older adults, mild cognitive impairment and Alzheimer’s disease: Results from the Australian Imaging, Biomarkers and Lifestyle – Rate of Change sub-study (AIBL-ROCS). Archives of Clinical Neuropsychology 28(4): 320-330.
Lothian A, Hare D, Masters C, Ryan T, Grimm R, Roberts BR (2013) Metalloproteomics: Principles, challenges and applications to neurodegeneration. Frontiers in Aging Neuroscience 5:35.
Moller M, Du Preez JL, Vilijoen FP, Berk M, Emsley R, Harvey BH (2013) N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metabolic Brain Disease 28(4): 687-96.
Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA; AIBL Investigators (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36: 2981-87. Erratum in: Diabetes Care 36: 3850.
Morris G, Anderson G, Berk M, Maes M (2013) Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Molecular Neurobiology 48(3): 883-903.
Nisbet RN, Nuttall SD, Caine JM, Robert R, Hittaki M, Pearce LA, Davydova N, Masters CL, Varghese JN, Streltsov VA (2013) Structural studies of the tethered N-terminus of the Alzheimer’s disease AB peptide. Proteins: Structure, Function and Bioinformatics, 81: 1748-1758.
Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, Streltsov VA, Opazo C, Aguayo LG (2013) Inhibition of the synaptotoxicity induced by Aβ oligomers by a pentapeptide derived from the glycine zipper region of the Aβ peptide. Neurobiology of Aging 34(12): 2805-2814.
Ripke S et al. [including Jablensky A]. (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45.10 (2013): 1150-1159.
Ripke S et al. [including Jablensky A] (2013).Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics 45: 1150-1159.
Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Folwer CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, Bush AI (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 34:171-182
Rembach A, Ryan T, Roberts B, Doecke J, Wilson W, Watt A, Barnham K, Masters C (2013) Progress towards consensus biomarkers for Alzheimer’s disease: a review of peripheral–based analytes. Biomarkers in Medicine 7: 1-22.
Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer’s disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology 74: 905-913.
Ryan TM, Caine J, Mertens HDT, Kirby N, Nigro J, Breheney K, Waddington LJ, Streltsov VA, Curtain C, Masters CL, Roberts BR (2013) Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ, DOI 10.7717/peerj.73.
Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, Girardi P, Brennan SL, Williams LJ (2013) Physical comorbidities in men with mood and anxiety disorders: a population-based study. BMC Medicine 11:110.
Scarr E, Craig JM, Cairns MJ, Seo MS, Galati JC, Beveridge NJ, Gibbons A, Juzva S, Weinrich B, Parkinson-Bates M, Carroll AP, Saffery R, Dean B (2013) Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Translational Psychiatry 3, e230.
Scarr E, Um JY, Cowie TF, Dean B (2013) Cholinergic muscarinic M4 receptor gene polymorphisms; a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophrenia Research 146: 279-284.
Schork AJ et al. [including Jablensky A] (2013) All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genetics 9.4: e1003449.
Streltsov VA, Epa VC, James SA, Churches QI, Caine JM, Kenche VB, Barnham KJ (2013) Structural insights into the interaction of platinum-based inhibitors with the Alzheimer’s disease amyloid-β peptide. Chemical Communications 49: 11364-11366.
Sumani Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of Nacetylcysteine. Biochimica et Biophysica Acta 1830: 4117–4129.
Terwisscha van Scheltinga AF et al. [including Jablensky A] (2013) Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. Biological Psychiatry 73: 525-531.
Vargas HO, Nunes SO, Pizzo de Castro M, Cristina Bortolasci C, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S, Maes M, Berk M (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. Journal of Affective Disorders 150(3): 923-30.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins RN, Maruff P, Ames D, Rowe CC, Masters CL, for the Australian Imaging Biomarkers and Lifestyle Research Group (2013) Aβ deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurology 12: 357-367.
Anderson G, Maes M, Berk M (2012) Biological underpinnings of the commonalities in depression, somatisation and chronic fatigue syndrome. Medical Hypotheses, 78: 752-753.
Anderson G, Maes M, Berk M (2012) Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Advances in Protein Chemistry and Structural Biology, 88: 27-48.
Anderson RJ, Frye MA, Lee KH, McGillivray JA, Berk M, Tye SJ (2012) Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neuroscience and Biobehavioral Reviews, 36: 1920-1933.
Bauer M, Glenn T, Alda M, Andreassen OA, Ardau R, Berk M et al (2012) Impact of sunlight on the age of onset of bipolar disorder, 14: 654-663.
Bechdolf A, Ratheesh A, Wood J, Tecic T, Conus P, Nelson B, Cotton S, Chanen A, Amminger G, Ruhrmann S, Schultze-Lutte F, Klosterkotter J, Fusar Poli P, Yung AR, Berk M, McGorry PD (2012) Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. 18: 358-375.
Bechdolf A, Wood SJ, Nelson B, Velakoulis D, Yucel M, Takahashi T, Yung AR, Berk M, Wong WT, Pantelis C, McGorry PD (2012) Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Research, 201: 34-39.
Berk M (2012) Is Australian psychiatry getting SHIP shape? Australian and New Zealand Journal of Psychiatry, 46: 801-802.
Berk M, Berk L, Davey CG, Moylan S, Giorlando F, Singh AB, Kalra H, Dodd S, Malhi GS (2012) Treatment of bipolar depression, MJA Open, 1: 32-35.
Berk M, Berk L, Dodd S, Jacka FN, Fitzgerald B, de Castella AR, Fillia S, Dillia K, Kulkarni J, Jackson HJ, Stafford L (2012) Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale, Journal of Evaluation in Clinical Practice, 18: 360-364.
Berk M, Berk L, Udina M, Moylan S, Stafford L, Hallam K, Goldstone S, McGorry PD (2012) Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale, Australian and New Zealand Journal of Psychiatry, 46: 92-99.
Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomised placebo controlled trial, BMC Medicine 10: 91.
Berk M, Jacka F (2012) Preventive strategies in depression: gathering evidence for risk factors and potential interventions. British Journal of Pharmacology, 201: 339-341.
Bromberg A, Lerer E, Udawela M, Scarr E, Dean B, Belmaker RH, Ebstein R, Agam G (2012) Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels. International Journal of Neuropyschopharamcology, 15: 727-737.
Chetelat G, Rowe CC, Villemagne VL. (2012) Amyloid Imaging in Alzheimer’s Disease: Relationships to Memory Deficits, Brain Atrophy, and Hypometabolism. European Neurological Journal 4: 61-68.
Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC (2012) Relationships between memory performances and [beta]-amyloid deposition at different stages of Alzheimer’s disease. Neurodegenerative Diseases, 10: 141-144.
Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high [beta]-amyloid deposition. Neurology, 78: 477-484.
Conn CE, Darmanin C, Mulet X, Hawley A, Drummond CJ (2012) Effect of lipid architecture on cubic phase susceptibility to crystallisation screens. Soft Matter, 8: 6884-6896.
Conn CE, Darmanin C, Mulet X, LeCann S, Kirby N, Drummond CJ (2012) High-throughput analysis of the structural evolution of the monoolein cubic phase in situ under crystallogenesis conditions. Soft Matter, in print.
Cotton SM, Lambert M, Schimmelmann BG, Gleeson JFM, Berk M, Hides L, Chanen A, McGorry PD, Conus P (2012) Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophrenia Research, 134: 20-26.
Darmanin C, Conn CE, Newman J, Mulet X, Seabrook SA, Liang Y-L, Hawley A, Kirby N, Varghese JN, Drummond CJ (2012) High-throughput production and structural characterisation of libraries of self-assembly lipidic cubic phase materials. ACS Combinatorial Science, 14: 247-252.
Dean B (2012) Editorial: Cholinergic muscarinic receptors: New opportunities as drug targets to treat psychiatric disorders. Future medicinal chemistry, 5: 1-3.
Dean B (2012) Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Current Pharmaceutical Biotechnology, 13: 1563-1571.
Dean B (2012) Neurochemistry of schizophrenia and psychosis: the contribution of neuroimaging. Current topics in medicinal chemistry, 12: 2375-2392.
Dean OM, Bush AI, Berk M (2012) Translating the Rosetta stone of N-acetyl cysteine. Biological Psychiatry, 71: 935-996.
Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hun M, Berk M (2012) Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences, 66: 514-517.
Dean OM, Data-Franco J, Giorlando F, Berk M (2012) Minocycline: therapeutic potential in psychiatry. CNS Drugs, 26: 391-401.
Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, Van Berckel BN, Wanner M (2012) SNM practice guideline for dopamine transporter imaging with 123O-Ioflupane SPECT. Protein Science, 20:457-464.
Doeke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer’s Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Study of Ageing (2012) Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Archives of Neurology, 69: 1318-1325.
Epa V, Streltsov V, Varghese J (2012) Computational studies on the stability of C-terminal beta-amyloid dimer and mutants. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 8: 718.
Green MJ, Cairns MJ, Wu, J, Dragovic M, Jablensky A, Tooney PA, Scott RJ, Carr VJ (2012) Genome-wide supported variant MIR317 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Molecular Psychiatry.
Jablensky A (2012) The disease entity in psychiatry: fact or fiction? Epidemiology and Psychiatric Services, 21: 255-264
Jacka FN, Berk (2012) Depression, diet and exercise. MJA Open, 1: 21-23.
Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M (2012). Nutrient intakes and the common mental disorders in women. Journal of Affective Disorders. Epub ahead of publication.
Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M (2012). Red meat consumption and mood and anxiety disorders. Pyschotherapy and Pyschosomatics, 81: 196-198.
Macneil CA, Hallam K, Conus P, Henry L, Kader L, Berk M (2012) Are we missing opportunities for early intervention in bipolar disorder? Expert Review Neurotherapy, 12: 5-7.
Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B (2012) Depression and sickness behaviour are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 29: 66.
Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant and neuroprogressive pathways and new drug candidates- NRF2 activators and GSK-3 inhibitors. Inflammopharmcology, 20: 127-150.
Maes M, Kubera M, Leunis JC, Berk M (2012) Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased translocation or leaky gut. Journal of Affective Disorders.
Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2012) In depression, bacterial translocation may drive inflammatory responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica.
Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2012) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. Journal of Affective Disorders
Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders., 136: 386-392.
Magalhaes PVS, Dean O, Andreazza AC, Berk M, Kapczinski F (2012) Adjunctive antioxidants for bipolar disorder (Protocol). Cochrane Review.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, Kolmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2012) Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuro-Psychophamacology and Brain Psychiatry, 37: 132-135.
Magalhaes PV, Dodd S, Nierenberg AA, Berk M (2012) Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD) Australian & New Zealand Journal of Psychiatry, 46: 1017-1018..
Magalhaes PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M (2012) Illness burder and medical comordibity in the systematic treatment enhancement program for bipolar disorder. Acta Psychiatrica Sandinavica, 125: 303-308.
Malhi GS, Bargh DM, McIntye R, Gitlin M, Frye MA, Bauer M, Berk M (2012) Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disorders, 14: 1-21.
Malhi GS, Berk M (2012) Is the safety of lithium no longer in the balance? Lancet, 379: 690-692.
Malhi GS, Tanious M, Das P, Berk M (2012) The science and practice of lithium therapy Australian New Zealand Journal of Psychiatry, 46: 192-211.
Macneil CA, Hasty M, Cotton S, Berk M, Hallam K, Kader L, McGorry P, Conus P (2012) Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study, Early Intervention in Psychiatry, 6: 380-388.
Markanday S, Data-Franco J, Dyson L, Murrant S, Arbuckle C, McGillvray J, Berk M (2012) Acceptance and commitment therapy for treatment-resistant depression. Bipolar Disorders, 46: 1198-1199.
Maud C, Berk M (2012) Neuropsychiatric presentation of Lyme disease in Australia Australian New Zealand Journal of Psychiatry.
McGorry PD, Berk M, Berk L, Goldstone S (2012) Commentary on ‘Palliative models of car for later stages of mental disorder: Maximising recovery, maintaining hope and building morale’, Australian New Zealand Journal of Pyschiatry, 46: 276-278.
Moylan S, Giorlando F, Nordfjaern T, Berk M (2012) The role of alprazolam for the treatment of panic disorder in Australia. Australian New Zealand Journal of Pyschiatry, 46: 212-224.
Moylan S, Maes M, Wray NR, Berk M (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry 18: 595-606.
Nunes SO, Vargas HO, Brum J, Prado E, Bargas MM, de Castro MR, Dodd S, Berk M (2012) A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tobacco Research, 14: 540-546.
Pasco JA, Jacka FN, Williams LJ, Evans-Cleverdon M, Brennan SL, Kotowicz MA, Nicholson GC, Ball MJ, Berk M (2012) Dietary selenium and major depression: a nested case-control study. Complementary Therapies in Medicine, 20: 119-193.
Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, Jacka FN, Schweitzer I (2012) Complementary medicine, exercise, meditation, diet and lifestyle modification for anxiety disorders: a review of current evidence. Evidence-based complementary and alternative medicine.
Scarr E (2012) Muscarinic M1 receptor agonists: can they improve cognitive performance in humans? International Journal of Neuropyschophamacology.
Scarr E (2012) Muscarinic receptors: Their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neuroscience & Therapeutics, 18: 369-379.
Scarr E, Dean B (2012) Altered neuronal markers following treatment with mood stabliser and antipsychotic drugs indicate an increased likelihood of neurotransmitter release. Clinical Pyschopharmacology and Neuroscience, 10: 25-33.
Scarr E, Money TT, Pavey G, Neo J, Dean B (2012) Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Pyschiatry 12: 126.
Scarr E, Sundram S, Dejo A, Cowie TF, Gibbons AS, Juva S, Mackinnon A, Wood SJ, Testa R, Pantelis C, Dean B (2012) Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. Schizophrenia Research, 138: 94-98.
Sona A, Zhang P, Ames D, Bush AI, Lautenschalger NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA and the AIBL Research Group (2012) Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24: 197-204.
Steinberg S et al. [including Jablensky A] (2012) Common variant at 16q11.2 conferring risk of psychosis. Molecular Psychiatry doi:10.1038/mp.2012.157
Streltsov VA, James S, de Jonge M, Howard D, Paterson D, Sankovich S, Caine J (2012) Imaging of beta-amyloid metal binding in yeast with x-ray fluorescence microscopy. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 8: 657-658.
Svendal G, Berk M, Pasco JA, Jacka FN, Lund A, Williams LJ (2012) The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140: 92-96.
Tang B, Dean B, Thomas EA (2012) Differential age- and disease-related effects of the expression of genes related to the arachidonic acid signaling pathway in schizophrenia, Psychiatry Research, 196: 201-206.
Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT Ikonomovic et al (2012) A-[beta] imaging: feasible, pertinent and vital to progress in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 39: 209-219.
Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN; for the AIBL Research Group (2012) Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Molecular Psychiatry 23. doi: 10.1038/mp.2012.147.
Villain N, Chetelat G, Grassiot B, P Bourgeat, G Jones, KA Ellis, D Ames, RN Martins, F Eustache, O Salvado, Masters CL, Rowe CC, Villemagne VL (2012) Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 135: 2126-2139.
Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC (2012) Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases 10: 161-165.
Villemagne VL, Rowe CC (2012) Long Night’s Journey into the Day: Amyloid-β Imaging in Alzheimer’s Disease. Journal of Alzheimers Disease 33: S349-359.
Williams LJ, Pasco JA, Jacka FN, Dodd S, Berk M (2012) Pain and the relationship with mood and anxiety disorders and psychological symptoms. Journal of Psychosomatic Research, 72: 452-456.
Badcock P B, Moore E, Williamson E, Berk M, Williams L J, Bjerkeset O, Nordahl H M, Patton G C, and Olsson C A (2011) Modeling gene‐environment interaction in longitudinal data: Risk for neuroticism due to interaction between maternal care and the Dopamine 4 Receptor gene (DRD4). Australian journal of psychology 63: 18-25.
Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O (2011) Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. Journal of Affective Disorders, 131: 207-213.
Berk M, Malhi GS (2011) Should antipsychotics take pole position in mania treatment? Lancet, 378: 1279-1281.
Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi G S, Berk L, Conus P, and McGorry P D. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar disorders, 13: 87-98.
Caine JM, Bharadwaj PR, SankovichSE, Ciccotosto GD, Streltsov VA, Varghese JN (2011) Oligomerization and toxicity of Aβ fusion proteins. Biochemical and Biophysical Research Communications, 409 (3), 477-482.
Conn CE, Mulet X, Moghaddam M, Darmanin C, Waddington LJ, Sagnella SM, Kirby N, Varghese JN, Drummond CJ (2011) Enhanced uptake of an integral membrane protein, the dopamine D2L receptor, by cubic nanoparticles doped with Ni chelated EDTA amphiphiles. Soft Matter, 7: 567-578.
Dilanian RA, Darmanin C, Varghese JN, Wilkins SW, Oka T, Yagi N, Quiney HM, Nugent KA (2011) Structural analysis of two-dimensional membrane protein crystals using x-ray powder diffraction data. Protein Science, 20: 457-464.
Gupta V, Wilson A, Rainey-Smith S, Laws S, Bush A, Ellis K, Macaulay L, Rowe C, Szoeke C, Taddei K, Ames D, Masters C, Martins R et al (2011) Establishing apolipoprotein E as a biomarker for Alzheimer’s disease: Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 110-111.
Hung LW, Villemagne VL, Cheng L et al (2012) The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor cognitive functions in multiple animal models of Parkinson’s disease. Journal of Experimental Medicine, accepted.
Jacka, F. N., Pasco, J. A., Mykletun, A., Williams, L. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2011). Diet quality in bipolar disorder in a population-based sample of women. Journal of affective disorders, 129(1), 332-337.
Laws S, Lam CP, Mondal A, Bush A, Ellis K, Macaulay L, Rowe C, Taddei K, Szoeke C, Ames D, Masters C, Martins R (2011) Gene combination associations with Alzheimer’s disease risk and quantitative traits in the AIBL study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 678-679.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Revista Brasileira de Psiquiatria, 33: 374-378.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, and Berk M (2011) N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of affective disorders 129:317-320.
Rainey-Smith S, Brown B, de Ruyck K, Laws S, Wilson A, Gupta V, Ames D, Ellis K, Taddei K, Head R, Macaulay L, Masters C, Rowe C, Szoeke C, Martins R et al (2011) Alzheimer’s disease related changes in plasma brain-derived neurotropic factor levels. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 407-408.
Williams LJ, Brennan SL, Henry MJ, Berk M, Jacka FN, Nicholson GC, Kotowicz MA, Pasco JA (2011) Area-based socioeconomic status and mood disorders: cross-sectional evidence from a cohort of randomly selected adult women. Maturitas, 69: 173-178.
Williams LJ, Pasco JA, Jacka FN, Henry MJ, Dodd S, Nicholson GC, Kotowicz MA, Berk M (2011) Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans. Acta Neuropsychiatrica, 23: 219-223.